CA2599988A1 - Methods and compositions for modulating hyperstabilized c-met - Google Patents
Methods and compositions for modulating hyperstabilized c-met Download PDFInfo
- Publication number
- CA2599988A1 CA2599988A1 CA002599988A CA2599988A CA2599988A1 CA 2599988 A1 CA2599988 A1 CA 2599988A1 CA 002599988 A CA002599988 A CA 002599988A CA 2599988 A CA2599988 A CA 2599988A CA 2599988 A1 CA2599988 A1 CA 2599988A1
- Authority
- CA
- Canada
- Prior art keywords
- met
- antibody
- antagonist
- cell
- hyperstabilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66548205P | 2005-03-25 | 2005-03-25 | |
| US60/665,482 | 2005-03-25 | ||
| PCT/US2006/010850 WO2006104911A2 (en) | 2005-03-25 | 2006-03-24 | Methods and compositions for modulating hyperstabilized c-met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2599988A1 true CA2599988A1 (en) | 2006-10-05 |
Family
ID=37053941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002599988A Abandoned CA2599988A1 (en) | 2005-03-25 | 2006-03-24 | Methods and compositions for modulating hyperstabilized c-met |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7615529B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1868648B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008535821A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080000613A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101184506B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006229989B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0611468A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2599988A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2539790T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL185708A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007011652A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20075412L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ561211A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2404193C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG159547A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006104911A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200707953B (cg-RX-API-DMAC7.html) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615529B2 (en) * | 2005-03-25 | 2009-11-10 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| SG188802A1 (en) * | 2008-03-06 | 2013-04-30 | Genentech Inc | Combination therapy with c-met and egfr antagonists |
| KR101837053B1 (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체 |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| CN102361884A (zh) * | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-2/抗-c-Met抗体 |
| CN102378768A (zh) * | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-3/抗-c-Met抗体 |
| NZ616382A (en) | 2009-04-20 | 2015-04-24 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17 |
| KR101671378B1 (ko) * | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
| KR101968766B1 (ko) | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | 이종 폴리펩티드의 분비를 위한 방법 및 조성물 |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| CN103534268B (zh) * | 2010-10-20 | 2016-05-18 | 牛津生物疗法有限公司 | 抗体 |
| RU2013155695A (ru) | 2011-06-30 | 2015-08-10 | Дженентек, Инк. | Препараты антител против с-мет |
| WO2013033008A2 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| EP2758430A4 (en) | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
| WO2013049112A1 (en) * | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| SG11201402485UA (en) * | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
| EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| SG11201506451UA (en) | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9567641B2 (en) * | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| SG11201607519VA (en) | 2014-03-14 | 2016-10-28 | Genentech Inc | Methods and compositions for secretion of heterologous polypeptides |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX378108B (es) | 2014-09-16 | 2025-03-10 | Servier Lab | Anticuerpos anti-met y composiciones. |
| GB201419108D0 (en) * | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| KR20170136536A (ko) | 2015-03-16 | 2017-12-11 | 셀덱스 쎄라퓨틱스, 인크. | 항-met 항체 및 그 사용 방법 |
| MX2019002946A (es) | 2016-09-14 | 2019-09-26 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos. |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
| MX2020010813A (es) | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| CA3106403A1 (en) | 2018-07-15 | 2020-01-23 | Enochian BioPharma, Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| BR112022015140A2 (pt) | 2020-02-12 | 2022-10-11 | Janssen Biotech Inc | Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| CN114478788B (zh) | 2020-11-11 | 2025-07-18 | 北京免疫方舟医药科技有限公司 | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| ATE423852T1 (de) | 1996-04-05 | 2009-03-15 | Antonio Giordano | Methoden zur diagnose und prognose von krebs |
| ATE465257T1 (de) * | 1996-07-03 | 2010-05-15 | Genentech Inc | Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen |
| DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| US20030228319A1 (en) * | 2002-04-16 | 2003-12-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| MXPA05008521A (es) * | 2003-02-13 | 2005-10-20 | Pharmacia Corp | Anticuerpos a c-met para el tratamiento de canceres. |
| WO2005001486A1 (en) * | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| CN1922208A (zh) * | 2003-12-11 | 2007-02-28 | 健泰科生物技术公司 | 用于抑制c-met二聚化及活化的方法和组合物 |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| US20060263808A1 (en) | 2005-03-25 | 2006-11-23 | Genentech, Inc. | C-met mutations in lung cancer |
| US7615529B2 (en) | 2005-03-25 | 2009-11-10 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
-
2006
- 2006-03-24 US US11/388,757 patent/US7615529B2/en not_active Expired - Lifetime
- 2006-03-24 WO PCT/US2006/010850 patent/WO2006104911A2/en not_active Ceased
- 2006-03-24 CA CA002599988A patent/CA2599988A1/en not_active Abandoned
- 2006-03-24 AU AU2006229989A patent/AU2006229989B2/en not_active Expired
- 2006-03-24 BR BRPI0611468-7A patent/BRPI0611468A2/pt not_active Application Discontinuation
- 2006-03-24 NZ NZ561211A patent/NZ561211A/en not_active IP Right Cessation
- 2006-03-24 MX MX2007011652A patent/MX2007011652A/es active IP Right Grant
- 2006-03-24 CN CN2006800183951A patent/CN101184506B/zh not_active Expired - Lifetime
- 2006-03-24 SG SG201000940-5A patent/SG159547A1/en unknown
- 2006-03-24 ES ES06748671.2T patent/ES2539790T3/es not_active Expired - Lifetime
- 2006-03-24 JP JP2008503236A patent/JP2008535821A/ja active Pending
- 2006-03-24 ZA ZA200707953A patent/ZA200707953B/xx unknown
- 2006-03-24 EP EP06748671.2A patent/EP1868648B1/en not_active Expired - Lifetime
- 2006-03-24 RU RU2007139452/10A patent/RU2404193C2/ru active
- 2006-03-24 KR KR1020077024503A patent/KR20080000613A/ko not_active Ceased
-
2007
- 2007-09-04 IL IL185708A patent/IL185708A/en active IP Right Grant
- 2007-10-24 NO NO20075412A patent/NO20075412L/no not_active Application Discontinuation
-
2009
- 2009-09-29 US US12/569,552 patent/US8536118B2/en active Active
-
2012
- 2012-05-22 JP JP2012116934A patent/JP2012232979A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006104911A3 (en) | 2007-02-22 |
| KR20080000613A (ko) | 2008-01-02 |
| RU2404193C2 (ru) | 2010-11-20 |
| US7615529B2 (en) | 2009-11-10 |
| WO2006104911A2 (en) | 2006-10-05 |
| NZ561211A (en) | 2011-03-31 |
| AU2006229989A1 (en) | 2006-10-05 |
| HK1109075A1 (en) | 2008-05-30 |
| CN101184506A (zh) | 2008-05-21 |
| JP2008535821A (ja) | 2008-09-04 |
| EP1868648A2 (en) | 2007-12-26 |
| US8536118B2 (en) | 2013-09-17 |
| ZA200707953B (en) | 2009-06-24 |
| MX2007011652A (es) | 2007-11-14 |
| CN101184506B (zh) | 2013-07-17 |
| AU2006229989B2 (en) | 2012-02-02 |
| IL185708A (en) | 2014-11-30 |
| JP2012232979A (ja) | 2012-11-29 |
| EP1868648B1 (en) | 2015-04-15 |
| BRPI0611468A2 (pt) | 2010-09-08 |
| US20060270594A1 (en) | 2006-11-30 |
| US20100028337A1 (en) | 2010-02-04 |
| IL185708A0 (en) | 2008-01-06 |
| ES2539790T3 (es) | 2015-07-06 |
| RU2007139452A (ru) | 2009-04-27 |
| SG159547A1 (en) | 2010-03-30 |
| NO20075412L (no) | 2007-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006229989B2 (en) | Methods and compositions for modulating hyperstabilized c-met | |
| US12583937B2 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP2538981B1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP2135881A1 (en) | Antibodies binding to the tumour associated antigen TAT10772 for the diagnosis and treatment of tumor | |
| US20170129963A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| DK2294197T3 (en) | VARIANT HHIP1 PROTEIN AND METHODS AND APPLICATIONS THEREOF | |
| HK1109075B (en) | Methods and compositions for modulating hyperstabilized c-met |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140812 |